Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• AMLX Q1 2026: Avexatide Phase III Completion Sets Up Pivotal Q3 Data Readout
  May 07, 2026
• Amylix Pharmaceuticals (AMLX) Q4 2025: Cash Runway Extended to 2028 as Lucidity Phase 3 Nears Key Data
  March 03, 2026
• Amylix Pharmaceuticals (AMLX) Q3 2025: Cash Position Rises to $344M as Avexitide Phase 3 Data Pushed to Q3 2026
  November 06, 2025
• AMLX Q2 2025: R&D Spend Up 17% as Avexatide Phase 3 Nears Full Enrollment
  August 07, 2025
• Amylix Pharmaceuticals (AMLX) Q1 2025: Expenses Down 82% as Pipeline Milestones Stack Up
  July 06, 2025
• Amylx Pharmaceuticals (AMLX) Q3 2024: R&D Spend Drops 29% as Avexitide Phase III Readout Anchors Pipeline Focus
  November 07, 2024
• Amylix Pharmaceuticals (AMLX) Q2 2024: Avexatide Acquisition and 66% Event Reduction Signal Pipeline Reset
  August 08, 2024
• Amylix Pharmaceuticals (AMLX) Q1 2024: 70% Workforce Cut Resets Pipeline Focus, Cash Runway Extends to 2026
  May 09, 2024
• Amylix (AMLX) Q4 2023: International Revenue Jumps as U.S. ALS Patient Base Holds Steady
  February 22, 2024
• AMLX Q3 2023: Discontinuation Rate Hits 40%, Spotlighting Persistency Challenge Ahead of Phoenix Data
  November 09, 2023

Browse all companies